| Recruiting | Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors Advanced or Metastatic Solid Tumors | Phase 1 | 2025-01-24 |
| Terminated | Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma Non Hodgkin Lymphoma | Phase 1 / Phase 2 | 2024-03-04 |
| Recruiting | IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) Non Small Cell Lung Cancer | Phase 2 | 2023-06-23 |
| Completed | Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express Peripheral T Cell Lymphoma | Phase 1 | 2022-03-17 |
| Active Not Recruiting | IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome | Phase 2 | 2019-05-22 |
| Terminated | IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2018-09-07 |
| Completed | Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Hea Head and Neck Neoplasms | Phase 1 / Phase 2 | 2015-12-01 |
| Terminated | Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | 2015-11-09 |
| Completed | Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) Cutaneous T-Cell Lymphoma | Phase 1 | 2015-10-01 |
| Terminated | Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity Squamous Cell Carcinoma of the Oral Cavity | Phase 1 / Phase 2 | 2014-12-01 |
| Completed | Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR) Acute Myeloid Leukemia | Phase 2 | 2012-10-01 |
| Completed | Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis Inflammation, Rheumatoid Arthritis | Phase 1 | 2011-05-01 |
| Completed | Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients Wi Patients With Multiple Myeloma Experiencing a, First or Second Relapse | Phase 1 | 2010-09-01 |
| Completed | Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myel Smoldering Multiple Myeloma | Phase 2 | 2010-09-01 |
| Completed | Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multip Multiple Myeloma | Phase 2 | 2009-09-01 |
| Completed | An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multi Multiple Myeloma | Phase 1 | 2007-05-01 |
| Completed | A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antib Acute Myeloid Leukemia | Phase 1 | 2007-02-01 |